Multidisciplinary Approach to Fatigue

NCT ID: NCT05502224

Last Updated: 2022-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-19

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective longitudinal, single-center, non-randomized study for the implementation of an integrated multidisciplinary fatigue follow-up for young patients with breast cancer or germ cell tumour

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each patient will receive a full evaluation by a multidisciplinary evaluation by a multidisciplinary team during one day. This evaluation will take place between 1 and 3 months after the end of "acute" treatments. The team is composed of an oncologist, a psychologist, a physiotherapist, a dietician and a nurse-coach. The goal of this comprehensive evaluation is to :

* to detect organic or psychological factors (severe depression,...) contributing to fatigue.
* to evaluate in detail the impact of fatigue on the patient's daily life.
* to evaluate the patient's level of physical activity in order to propose an adequate and and personalized management. During this evaluation, the patient will be asked to discuss which aspects of his or her daily life he or she would like to improve as a priority. At the end of this complete evaluation, each patient's case will be will be discussed in a multidisciplinary meeting with all the people involved in the program in order to propose a detailed and personalized treatment plan.

This plan will be explained in detail to the patient by the nurse-coach who will organize and coordinate the patient's care. The patient will receive the detailed management plan in writing.

The patient will receive the detailed management plan in writing, which will also be communicated to the patient's treating physicians.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Germ Cell Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Each individual is his own control. It is therefore a longitudinal data collection.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Specific fatigue management program

Group Type OTHER

Ergospirometry

Intervention Type OTHER

Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ergospirometry

Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 39 years at the time of signing the informed consent
* Patient who speaks and understands French
* Signed study informed consent form obtained prior to any study related procedures
* At minimum, a moderate (\>3) fatigue level according to the Standard Rating Scale (NRS) 1 month after completion of acute treatment; as measured at the Survivorship of the standard program
* Patient with either: curative breast cancer (AJCC stage I-II-III) or a germ cell tumor

Exclusion Criteria

* Refusal to participate in the study
* Patient having chosen to participate in another psychosocial intervention study for the duration of the study.
* Patients with AJCC stage IV breast cancer
Minimum Eligible Age

18 Years

Maximum Eligible Age

39 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jules Bordet Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Jules Bordet

Brussels, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laura Polastro, MD

Role: CONTACT

+3225413279

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Laura Polastro, MD

Role: primary

+32 (0) 2 541 3279

Caroline Defays

Role: backup

+32 (0) 2 541 3966

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IJB-PRINTEMPS-2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.